Semaglutide (Ozempic) was tied to a reduced risk of Alzheimer's disease diagnoses in people with type 2 diabetes, ...

Though Lilly has been in the spotlight for the success of its GLP-1 drugs, the pharma giant has also been investing in a corporate brand campaign to boost its overall reputation.

The company is suing some online vendors and medical spas for selling copycats of a weight loss and diabetes drug.

Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...

Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...

A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims ...

Weaver Capital Management LLC lessened its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 1.0% in the 3rd quarter ...

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo ...

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims ...

The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...

Pharmacies currently making copycat versions of Eli Lilly’s tirzepatide face heightened exposure to state enforcement actions ...